CAPPELLI, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.999
AS - Asia 9.455
EU - Europa 8.153
SA - Sud America 1.053
Continente sconosciuto - Info sul continente non disponibili 313
AF - Africa 244
OC - Oceania 123
Totale 30.340
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.686
RU - Federazione Russa 3.072
SG - Singapore 2.860
CN - Cina 2.829
IT - Italia 1.893
HK - Hong Kong 938
KR - Corea 872
BR - Brasile 809
VN - Vietnam 774
PL - Polonia 619
IE - Irlanda 515
FI - Finlandia 458
SE - Svezia 343
DE - Germania 340
BD - Bangladesh 301
FR - Francia 279
IN - India 258
GB - Regno Unito 189
CA - Canada 167
AU - Australia 122
JP - Giappone 117
NL - Olanda 112
ID - Indonesia 111
TR - Turchia 95
AR - Argentina 93
JO - Giordania 91
ES - Italia 81
MX - Messico 80
NG - Nigeria 51
EG - Egitto 50
UA - Ucraina 49
EC - Ecuador 42
ZA - Sudafrica 39
IQ - Iraq 36
PK - Pakistan 34
PT - Portogallo 33
CH - Svizzera 32
VE - Venezuela 26
AT - Austria 24
BJ - Benin 23
SA - Arabia Saudita 22
CL - Cile 21
BE - Belgio 19
CO - Colombia 19
LT - Lituania 18
MA - Marocco 17
MY - Malesia 17
DK - Danimarca 15
PY - Paraguay 15
UZ - Uzbekistan 15
KE - Kenya 14
CI - Costa d'Avorio 12
TN - Tunisia 12
AE - Emirati Arabi Uniti 10
JM - Giamaica 9
PH - Filippine 9
AL - Albania 8
BO - Bolivia 8
CR - Costa Rica 8
NP - Nepal 8
PA - Panama 8
PE - Perù 8
TT - Trinidad e Tobago 8
UY - Uruguay 8
GR - Grecia 7
HN - Honduras 7
CZ - Repubblica Ceca 6
DZ - Algeria 6
PR - Porto Rico 6
BG - Bulgaria 5
BH - Bahrain 5
KZ - Kazakistan 5
LV - Lettonia 5
NO - Norvegia 5
RS - Serbia 5
TH - Thailandia 5
TW - Taiwan 5
AZ - Azerbaigian 4
BW - Botswana 4
GT - Guatemala 4
HR - Croazia 4
KG - Kirghizistan 4
NI - Nicaragua 4
PS - Palestinian Territory 4
RO - Romania 4
BY - Bielorussia 3
IR - Iran 3
LB - Libano 3
QA - Qatar 3
SC - Seychelles 3
SY - Repubblica araba siriana 3
AO - Angola 2
CG - Congo 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GY - Guiana 2
IL - Israele 2
KW - Kuwait 2
LK - Sri Lanka 2
MD - Moldavia 2
Totale 29.991
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.698
Singapore 2.168
Ashburn 1.537
Hefei 1.076
Seoul 869
Hong Kong 833
Warsaw 611
San Jose 574
Dublin 512
Fairfield 488
Milan 327
Helsinki 324
Beijing 292
Los Angeles 258
Ho Chi Minh City 254
Chandler 253
Council Bluffs 226
Woodbridge 200
Rome 195
Houston 194
Seattle 187
New York 177
Moscow 174
Florence 173
Hanoi 171
Buffalo 166
Lauterbourg 164
Cambridge 161
The Dalles 156
Wilmington 148
Kent 135
Munich 131
Melbourne 114
Dallas 106
Lawrence 103
Altamura 100
Ann Arbor 95
Tokyo 94
Jakarta 82
São Paulo 80
Chicago 78
Mumbai 77
Princeton 74
Shanghai 74
Naples 70
Boston 59
Lappeenranta 59
Bengaluru 58
Frankfurt am Main 53
Abuja 48
Phoenix 48
San Diego 48
Turku 47
Orem 43
Medford 42
Boardman 41
Da Nang 41
Figino 41
Toronto 41
London 40
Guangzhou 39
Amsterdam 38
Paris 36
Rio de Janeiro 36
West Jordan 36
Bologna 34
Istanbul 34
Düsseldorf 32
Montreal 31
Turin 31
Atlanta 30
Brooklyn 30
Chennai 30
Denver 29
Haiphong 28
Jacksonville 28
Palermo 27
Mexico City 25
North Bergen 25
Padua 25
Redondo Beach 25
Yubileyny 25
Asheville 24
Dong Ket 24
Lisbon 24
Pune 24
San Francisco 24
Shenzhen 24
Cotonou 23
Stockholm 23
Johannesburg 21
Bern 20
West Bloomfield 20
Belo Horizonte 19
Genoa 19
Pisa 19
Brussels 18
Hillsboro 18
Miano 18
Baghdad 17
Totale 18.741
Salva come PNG Salva come JPEG
Nome #
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy 520
Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian perspective 309
Semi-quantitative indices of cardiac uptake in patients with suspected cardiac amyloidosis undergoing 99mTc-HMDP scintigraphy 293
Lung uptake during 99mTc-hydroxymethylene diphosphonate scintigraphy in patient with TTR cardiac amyloidosis: An underestimated phenomenon 274
Biohumoral markers as predictor of right ventricular dysfunction in AL Amyloidosis. 234
Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis 232
Different NT-proBNP circulating levels for different types of cardiac amyloidosis 230
Real-world versus trial patients with transthyretin amyloid cardiomyopathy 223
Screening for cardiac amyloidosis in patients with tenosynovial red flags: A collaboration between family medicine and cardiology 220
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 220
Heart failure with mid-range ejection fraction: Current evidence and uncertainties 217
Clinical staging of Anderson-Fabry cardiomyopathy: An operative proposal 212
Standard Therapy in Cardiac Amyloidosis 211
Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis 205
Incidence and determinants of atrial fibrillation in patients with wild-type transthyretin cardiac amyloidosis 204
Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis 203
Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy: The Need for Disease-Specific Criteria 203
[Therapeutic approaches in hypertrophic cardiomyopathy: from symptom relief to precision therapy] 202
Determinants of health status in older patients with transthyretin cardiac amyloidosis: a prospective cohort study 199
Liver dysfunction as predictor of prognosis in patients with amyloidosis: utility of the Model for End-stage Liver disease (MELD) scoring system 199
Changes in the perceived epidemiology of amyloidosis: 20 year-experience from a Tertiary Referral Centre in Tuscany 199
A multidisciplinary case report of multiple myeloma with renal and cardiac involvement: a look beyond amyloidosis 197
Results of comprehensive cardiovascular diagnostic work-up in HIV positive patients 196
As we cannot afford to renounce to new generation echocardiography in systemic amyloidosis. 195
Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis 195
Depression and cardiac symptoms among AL amyloidosis patients: the mediating role of coping strategies. 194
Cerebral Fat Embolism After Video-Assisted Thoracic Surgery 192
Electromechanical dissociation of left atrium in patients with Cardiac Amyloidosis by Magnetic Resonance: Prognostic and clinical correlates 192
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience 190
Troponins in cardiac amyloidosis: multipurpose markers. 189
Clinical pathway for cardiomyopathies: A genetic testing strategy proposed by ANMCO in Tuscany 188
Arrhythmic Burden in Cardiac Amyloidosis: What We Know and What We Do Not 187
Clinical Importance of Left Atrial Infiltration in Cardiac Transthyretin Amyloidosis 183
QRS duration in left bundle branch block does not affect left ventricular twisting in chronic systolic heart failure 183
ECG abnormalities, atrial fibrillation and AV blocks in ATTR VS AL amyloidosis: an electrophysiological natural history 183
Abrupt onset of refractory heart failure associated with light-chain amyloidosis in hypertrophic cardiomyopathy 183
Anxiety and depression among amyloid light-chain cardiac amyloidosis patients: The role of life satisfaction. 181
Red flags for the diagnosis of cardiac amyloidosis: Simple suggestions to raise suspicion and achieve earlier diagnosis 178
Serial changes in CPET parameters in untreated patients with transthyretin cardiac amyloidosis 177
Prevalence of transthyretin-related amyloidosis in Tuscany: Data from the regional population-based registry 175
Amyloidosis in spinal stenosis: How, when and whether cardiac screening has a clinical impact 174
Incidence of stroke in patients with hypertrophic cardiomyopathy in stable sinus rhythm during long-term monitoring 174
Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study 174
Poor right ventricular function is associated with impaired exercise capacity and ventilatory efficiency in transthyretin cardiac amyloid patients 173
Atrial standstill disease progression documented after 13 years follow-up 172
Multicentre multi-device hybrid imaging study of coronary artery disease: Results from the EValuation of INtegrated Cardiac Imaging for the Detection and Characterization of Ischaemic Heart Disease (EVINCI) hybrid imaging population 171
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 171
Anxiety and depression among AL amyloidosis patients: The role of cardiac symptoms 171
Emerging Medical Treatment for Hypertrophic Cardiomyopathy 170
Tenosynovial complications identify TTR cardiac amyloidosis among patients with hypertrophic cardiomyopathy phenotype 170
Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy 169
Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems 169
Low Sensitivity of Bone Scintigraphy in Detecting Phe64Leu Mutation-Related Transthyretin Cardiac Amyloidosis 169
Early Diagnosis and Outcome in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 169
Measurement of myocardial amyloid deposition in systemic amyloidosis: Insights from cardiovascular magnetic resonance imaging 168
Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis 166
Echo/Doppler-derived time intervals are able to predict left ventricular reverse remodeling after cardiac resynchronization therapy 166
Cardiac amyloidosis in patient undergoing TAVR, why we need to think about it 166
Prevalence, causes and predictors of cardiovascular hospitalization in patients with hypertrophic cardiomyopathy 166
ATTRv amyloidosis Italian Registry: clinical and epidemiological data 166
The Role of T2 Mapping in Cardiac Amyloidosis 165
Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy 165
Orphan Drug Use in Patients With Rare Diseases: A Population-Based Cohort Study 165
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC-TIVE study, an Italian nationwide survey 165
Ventricular tachyarrhythmias and sudden cardiac death in light-chain amyloidosis: a clash of cardio-toxicities? 165
Investigation on the high recurrence of the ATTRv-causing transthyretin variant Val142Ile in central Italy 164
A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization - the first insight from the AC-TIVE Study 164
Temporal Variation in Optimal Atrioventricular and Interventricular Delay During Cardiac Resynchronization Therapy 164
Concordant Versus Discordant Left Bundle Branch Block in Heart Failure Patients: Novel Clinical Value of an Old Electrocardiographic Diagnosis 163
Racial Differences in Val122Ile-Associated Transthyretin Cardiac Amyloidosis 163
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy 163
Rotational mechanics of the left ventricle in AL amyloidosis 163
Aortic Stenosis and Cardiac Amyloidosis: PARTNERs in Crime? 161
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial 161
Caregiver’s psychological well-being and quality of relationship with cardiac amyloidosis patients 160
Clinical scenarios of HCM-related mortality: Relevance of age and stage of disease at presentation 160
SGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients series 160
The Italian Fabry Disease Cardiovascular Registry (IFDCR) 160
Anxious/Depressive Symptoms Alter the Subjective Perception of Heart Failure Severity in Transthyretin Cardiac Amyloidosis 160
Transthyretin Cardiac Amyloidosis: A Cardio-Orthopedic Disease 159
Progressive and atypical neurological symptoms in refractory systemic AL amyloidosis 158
Differential Diagnoses in Clinical Mimics 158
Diagnostic Pathways to Wild-Type Transthyretin Amyloid Cardiomyopathy: a Multicenter Network Study 157
Prognostic value of cardiopulmonary exercise testing in patients with transthyretin cardiac amyloidosis 157
Baseline ECG features and arrhythmic profile in transthyretin versus light chain cardiac amyloidosis 157
Impact of Pregnancy on the Natural History of Women with Hypertrophic Cardiomyopathy 157
From atrial fibrillation management to atrial myopathy assessment: the evolving concept of left atrium disease in hypertrophic cardiomyopathy 154
Is Hereditary Transthyretin Amyloidosis the Third Leading Cause of Monogenic Chronic Kidney Disease, Only Behind ADPKD and Alport Disease? 154
A Man in His 80s with Hypertension, Left Ventricular Hypertrophy, and Enlarged Biceps 153
Pathophysiology and Treatment of Hypertrophic Cardiomyopathy: New Perspectives 153
Wild-Type ATTR Amyloidosis 152
Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey 152
Role of cardiovascular magnetic resonance in the clinical evaluation of left ventricular hypertrophy: a 360° panorama 151
The Val142Ile transthyretin cardiac amyloidosis: more than an Afro-American pathogenic variant 151
Frailty and caregiver relationship quality in older patients diagnosed with transthyretin cardiac amyloidosis 150
Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value 150
Resynchronization of mitral valve annular segments reduces functional mitral regurgitation in cardiac resynchronization therapy 150
Prevalence of carpal tunnel syndrome in patients with transthyretin cardiac amyloidosis 149
Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis 149
Adaptative or maladaptative hypertrophy, different spatial distribution of myocardial contraction 149
Totale 18.272
Salva come PNG Salva come JPEG
Categoria #
all - tutte 89.732
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 89.732
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022567 16 27 20 20 18 39 15 34 44 97 80 157
2022/20231.796 99 319 88 77 124 319 337 103 186 31 72 41
2023/20241.381 24 116 135 59 112 171 61 334 39 136 102 92
2024/20258.991 292 879 475 1.372 2.236 1.160 224 440 445 242 515 711
2025/202614.669 1.384 2.040 1.912 1.384 1.252 551 1.526 793 1.099 807 709 1.212
2026/2027577 577 0 0 0 0 0 0 0 0 0 0 0
Totale 30.340